Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvocidib with Chemotherapy in Japanese AML Patients
NCT03563560Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- May 2018
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of alvocidib in acute myeloid leukemia (AML) (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Safety and tolerability evaluated by CTCAE v4.0 at 2 months. Started May 2018; status: completed.
02
Drugs
alvocidib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03563560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563560.